Pharming Group (NASDAQ:PHAR – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $7.82, but opened at $8.69. Pharming Group shares last traded at $8.69, with a volume of 3,699 shares trading hands.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Friday, May 31st.
Check Out Our Latest Analysis on PHAR
Pharming Group Stock Performance
Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.20). Pharming Group had a negative net margin of 4.01% and a negative return on equity of 4.61%. The firm had revenue of $55.59 million for the quarter, compared to analysts’ expectations of $68.43 million. On average, research analysts forecast that Pharming Group will post -0.03 earnings per share for the current year.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group (NASDAQ:PHAR – Free Report) by 32.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
- Five stocks we like better than Pharming Group
- Stock Analyst Ratings and Canadian Analyst Ratings
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- How to invest in marijuana stocks in 7 stepsĀ
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- Investing in Construction Stocks
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.